Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry).
Long-term outcomes of IVUS-guided and angiography-guided drug-eluting stent implantation for left main coronary artery disease: a retrospective consort study.
Yang Q, Ma X, Wang Y.
J Cardiothorac Surg. 2024 Jul 1;19(1):407. doi: 10.1186/s13019-024-02800-0.
Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
Kirtane AJ, Généreux P, Lewis B, Shlofmitz RA, Dohad S, Choudary J, Dahle T, Pineda AM, Shunk K, Maehara A, Popma A, Redfors B, Ali ZA, Krucoff M, Armstrong E, Kandzari DE, O'Neill W, Kraemer C, Stiefel KM, Jones DE, Chambers J, Stone GW; ECLIPSE Investigators.
Lancet. 2025 Apr 12;405(10486):1240-1251. doi: 10.1016/S0140-6736(25)00450-7. Epub 2025 Mar 30.
Is coronary artery tortuosity a predisposing factor for drug-eluting stent restenosis?
Levent F, Senoz O, Emren SV, Emren ZY, Gediz RB.
Herz. 2022 Feb;47(1):73-78. doi: 10.1007/s00059-021-05036-z. Epub 2021 Apr 24.
Coronary artery bypass graft surgery versus drug-eluting stent implantation for high-surgical-risk patients with left main or multivessel coronary artery disease.
Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ.
Eur J Cardiothorac Surg. 2017 May 1;51(5):943-949. doi: 10.1093/ejcts/ezw370.
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.
Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, Nilsen DW, Kløw NE, Uchto M, Trovik T, Bendz B, Stavnes S, Bjørnerheim R, Larsen AI, Slette M, Steigen T, Jakobsen OJ, Bleie Ø, Fossum E, Hanssen TA, Dahl-Eriksen Ø, Njølstad I, Rasmussen K, Wilsgaard T, Nordrehaug JE; NORSTENT Investigators.
N Engl J Med. 2016 Sep 29;375(13):1242-52. doi: 10.1056/NEJMoa1607991. Epub 2016 Aug 29.
Effect of lipoprotein(a) levels on long-term outcome in octogenarians with coronary artery disease after drug-eluting stent implantation.
Hu B, Zhou Y, Shi D, Zhao Y, Jia D, Yang S, Jia S, Xu X, Ma X.
Rev Cardiovasc Med. 2022 Mar 1;23(3):79. doi: 10.31083/j.rcm2303079.
Two-year outcomes of bioresorbable vascular scaffold versus drug-eluting stents in coronary artery disease: a meta-analysis.
Nairooz R, Saad M, Sardar P, Aronow WS.
Heart. 2017 Jul;103(14):1096-1103. doi: 10.1136/heartjnl-2016-310886. Epub 2017 Jan 23.
Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis.
Wang Z, Gong Y, Fan F, Yang F, Qiu L, Hong T, Huo Y.
Ren Fail. 2020 Nov;42(1):107-112. doi: 10.1080/0886022X.2019.1710187.
Comparison of the Effects of Indobufen and Aspirin in Older Patients with Coronary Artery Disease After Coronary Drug-Eluting Stent Implantation: A Prospective Randomized Single-Center Study.
Wu Y, Gao Z, Jin Q, Zheng J, Xu H, Tu X.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241309633. doi: 10.1177/10760296241309633.
Predictors of Irregular Protrusion After Everolimus-Eluting Stent Implantation in Patients with Stable Coronary Artery Disease.
Taguchi Y, Itoh T, Sasaki W, Oda H, Uchimura Y, Kaneko K, Sakamoto T, Goto I, Sakuma M, Ishida M, Terashita D, Otake H, Morino Y, Shinke T.
Int Heart J. 2022;63(2):210-216. doi: 10.1536/ihj.21-548.
